TABLE 2.

Inclusion and Exclusion Criteria

	Include	Exclude
Populations	Humans undergoing treatment for OUD (including pregnant women)	Patients undergoing treatment for detoxification only or acute withdrawal without post-detoxification follow-up;Patients undergoing treatment for pain with no concomitant OUD;Animal studies
Interventions and Comparisons	Transfer from BUP (or BUP/NLX) to METH	Any other medication interventions or comparisons;Studies that did not describe the transfer strategy for at least the first day;Studies that did not transfer directly from one to the other (e.g., exclude if morphine used between METH and BUP);Studies that included transfers and non-transfers but did not report stratified results
Outcomes	Precipitated withdrawal;Transfer completion;Post-transfer retention in treatment; Treatment adherence;Abstinence;Relapse;Mortality;Major clinical morbidity attributable to BUP or METH (overdose or serious adverse events∗)	Non-serious adverse events
Study Designs	Randomized and non-randomized controlled trials;Non-comparative and uncontrolled trials; Prospective and retrospective cohort studies;Case series	Pharmacokinetic and pharmacodynamic studies;Single case reports;Cost-effectiveness studies;Articles that did not contain original data (e.g., editorials, non-research letters, narrative reviews);Systematic reviews
Geography	No limit	NA
Study Duration	No minimum	NA
Languages	Any	NA

^∗As determined by FDA guidance at https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.

BUP indicates buprenorphine; METH, methadone; NA, not applicable; NLX, naloxone; OUD, opioid use disorder.